Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
Department of Molecular Genetics and Microbiology; Department of Medicine, Division of Diabetes; Department of Medicine, Division of Endocrinology and Metabolism
Animals; Antigens, Differentiation, T-Lymphocyte; CD40 Ligand; Crosses, Genetic; Diabetes Mellitus, Experimental; *Graft Survival; Islets of Langerhans Transplantation; *Lymphocyte Transfusion; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Transplantation, Homologous
Life Sciences | Medicine and Health Sciences
Combined treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to CD40 ligand (CD40L) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet donors at major and minor histocompatibility loci. The effect of the allogeneic small lymphocytes was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-CD40L by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that small lymphocytes expressing donor antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-CD40L antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet grafts.
Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9560-4.
Proceedings of the National Academy of Sciences of the United States of America
Parker, David C.; Greiner, Dale L.; Phillips, Nancy E.; Appel, Michael C.; Steele, Alan W.; Durie, Fiona H.; Noelle, Randolph J.; Mordes, John P.; and Rossini, Aldo A., "Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand" (1995). Open Access Articles. 1805.